Nanochon just did something quiet, surgical, and expensive in the way real progress usually is. A $4.1M oversubscribed Seed Prime II round closed, total capital now at $11.3M, and nobody involved is pretending this is about noise. This is about knees, physics, biology, and patience. The kind that does not fit neatly into quarterly updates but shows up years later in how someone walks, runs, or climbs stairs without thinking about it.
Founded in 2016 by Benjamin Holmes, Ph.D. and Nathan J. Castro, Ph.D., Nanochon started when two biomedical engineers at George Washington University decided cartilage deserved more than temporary fixes and crossed fingers. The company is headquartered in Washington, D.C., with manufacturing at The LaunchPort in Baltimore, an ISO13485 facility where medtech ideas either grow up or get exposed. No vibes, no shortcuts, just systems that have to work every time.
cultivate(MD) Capital Funds led this follow-on round, joined by the University of Virginia UVA Seed Fund, WSGR, Wealthing VC Fund, existing investors, and new capital that understands orthopedic timelines do not care about hype cycles. Cartilage regeneration does not respond to slogans. It responds to material science, biomechanics, and clinical discipline lining up like grown adults.
The product is Chondrograft™, a 3D-printed synthetic implant designed for active adults with focal cartilage defects who are too young for total knee replacement and too real for conservative care. Nylon-based composite. Immediate load-bearing. A porous structure that invites biology instead of fighting it. Press-fit, minimally invasive, compatible with existing surgical workflows. Off-the-shelf availability means no donor tissue and no waiting on custom manufacturing while patients sit in limbo.
In Jan 2026, Nanochon initiated its first-in-human Phase I clinical trial in Canada after Health Canada approval. Ten patients. Early feasibility. Real knees, real data. The study is running at Durham Bone & Joint Specialists in Ontario under Principal Investigator Dr. Fathi Abuzgaya, supported by a clinical team that knows the difference between optimism and evidence.
This capital sustains that trial, expands manufacturing in Baltimore, deepens R&D, and advances planning for a pivotal North American trial on the FDA PMA path toward a targeted 2029 launch. In parallel, Nanochon is building MRI-based preoperative planning software with ProVoyance, because hardware without software in 2026 is just unfinished business.
Benjamin Holmes, Ph.D. leads as CEO with a founder’s memory and an operator’s restraint. Nathan J. Castro, Ph.D. continues architecting the science as CTO. Matthew Scherer brings decades of capital markets discipline as CFO. Rachel Offenburg drives strategy with commercial clarity. Heather Neill keeps the clinical engine honest.
The cartilage repair market is projected to reach $3B by 2035. Roughly 700K knee arthroscopies happen every year in the U.S. Hundreds of thousands of patients live in the gap between rest and replacement. Nanochon is not chasing applause. It is building cartilage like time, surgeons, and outcomes are the only judges that matter.
